Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cachexia in rheumatoid arthritis.

Joseph Walsmith1, Ronenn Roubenoff

  • 1Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, USA.

International Journal of Cardiology
|August 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older Adults.

The Journal of clinical endocrinology and metabolism·2026
Same author

Correction: Clinical Classification of Cancer Cachexia: Phenotypic Correlates in Human Skeletal Muscle.

PloS one·2024
Same author

Sarcopenia: no consensus, no diagnostic criteria, and no approved indication-How did we get here?

GeroScience·2023
Same author

Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2023
Same author

Lessons Learned While Grieving.

Annals of internal medicine·2023
Same author

Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338).

Clinical pharmacokinetics·2022

Rheumatoid cachexia, a loss of body cell mass in rheumatoid arthritis, is driven by inflammatory cytokines and reduced insulin action. Physical exercise is the primary countermeasure, with future research focusing on anti-cytokine therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Metabolic Medicine

Background:

  • Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint destruction.
  • RA leads to rheumatoid cachexia, characterized by loss of body cell mass, muscle weakness, and reduced function.
  • Rheumatoid cachexia accelerates morbidity and mortality in RA patients.

Purpose of the Study:

  • To define rheumatoid cachexia.
  • To discuss the etiology, pathogenesis, and treatment of rheumatoid cachexia.
  • To highlight the role of cytokines and insulin resistance in RA muscle wasting.

Main Methods:

  • Review of current literature on rheumatoid cachexia.
  • Analysis of the role of tumor necrosis factor-alpha and interleukin-1beta in muscle wasting.

Related Experiment Videos

  • Examination of the impact of reduced insulin action and physical activity.

    • Main Results:

    • Rheumatoid cachexia involves elevated resting energy expenditure and protein catabolism.
    • Tumor necrosis factor-alpha and interleukin-1beta are key mediators of muscle wasting.
    • Reduced insulin action and low physical activity contribute significantly to rheumatoid cachexia.

    Conclusions:

    • Physical exercise, including strength training and aerobic exercise, is the most effective countermeasure.
    • Anti-cytokine therapy warrants further investigation for safety and efficacy.
    • Understanding the pathogenesis of rheumatoid cachexia is crucial for developing targeted treatments.